KR960706341A - 유기 인 콜린스테라아제 억제제에 의해 야기되는 중독의 예방 및 예비 치료를 위한 약제 제형(pharmaceutical formulation for preventing or pre-treating poisoning by organophosphoric cholinesterase inhibitors) - Google Patents

유기 인 콜린스테라아제 억제제에 의해 야기되는 중독의 예방 및 예비 치료를 위한 약제 제형(pharmaceutical formulation for preventing or pre-treating poisoning by organophosphoric cholinesterase inhibitors)

Info

Publication number
KR960706341A
KR960706341A KR1019960702987A KR19960702987A KR960706341A KR 960706341 A KR960706341 A KR 960706341A KR 1019960702987 A KR1019960702987 A KR 1019960702987A KR 19960702987 A KR19960702987 A KR 19960702987A KR 960706341 A KR960706341 A KR 960706341A
Authority
KR
South Korea
Prior art keywords
pharmaceutical formulation
parasympathetic
inhibitor
formulation according
active ingredient
Prior art date
Application number
KR1019960702987A
Other languages
English (en)
Other versions
KR100374086B1 (ko
Inventor
토마스 힐레
왈터 뮐러
보도 아스뮤젠
아하론 레비
야코프 메슐람
Original Assignee
플랭크 베커· 베르너 웨스링
엘티에스 로프만 써라피에-시스테메 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6504683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR960706341(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 플랭크 베커· 베르너 웨스링, 엘티에스 로프만 써라피에-시스테메 게엠베하 filed Critical 플랭크 베커· 베르너 웨스링
Publication of KR960706341A publication Critical patent/KR960706341A/ko
Application granted granted Critical
Publication of KR100374086B1 publication Critical patent/KR100374086B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 하나 이상의 부교감 신경 작용약 및 하나 이상의 부교감 신경 억제제의 활성 성분 조합물로 이루어지는 유기 인 콜린스테라아제 억제제에 의해 야기되는 중독의 예방 및 예비 치료를 위한 약제 제형에 관한 것이다.

Description

유기 인 콜린스테라아제 억제제에 의해 야기되는 중독의 예방 및 예비 치료를 위한 약제 제형(PHARMACEUTICAL FORMULATION FOR PREVENTING OR PRETREATING POISONING BY ORGANOPHOSPHORIC CHOLINESTERASE INHIBITORS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하나 이상의 부교감 신경 작용약 및 하나 이상의 부교감 신경 억제제로 이루어지는 활성 성분 조합물로 이루어지는, 유기 인 콜린스테라아제에 의해 야기되는 중독의 예방 및 예비 치료를 위한 약제 형성.
  2. 제1항에 있어서, 활성 성분 조합물의 경구 투여를 위한 투여 형태로 존재함을 특징으로 하는 약제 제형.
  3. 제1항에 있어서, 활성 성분 조합물의 비경구 투여를 위한 투여 형태로 존재함을 특징으로 하는 약제 제형.
  4. 제1항 내지 3항 중 어느 한 항에 있어서, 하나 이상의 활성 성분에 대한 저장 효과를 갖는 투여 형태로 존재함을 특징으로 한는 약제 제형.
  5. 제1항에 있어서, 부교감 신경 억제제가 트로판 알칼로이드, 이것의 염 라세미체 혼합물로 구성된 군으로부터 선택됨을 특징으로 하는 약제 제형.
  6. 제1항에 있어서, 부교감 신경 작용약이 간접적으로 효과적인 투여 형태로 존재함을 특징으로 하는 약제 제형.
  7. 제6항에 있어서, 간접적으로 효과적인 부교감 신경 작용약이 아세틸콜린스테라아제 억제제로 이루어짐을 특징으로 하는 약제 제형.
  8. 제7항에 있어서, 아세틸콜린스테라아제 억제제가 피소스티그민, 헵틸피소스티그민, 네오스티그민, 피리도스티그민, 갈란타민, 테트라히드로아 크리딘 및 벨나크리딘, 및 이들의 염 및 라세미 혼합물로 이루어짐을 특징으로 하는 약제 제형.
  9. 제1항에 있어서, 부교감 신경 작용약이 스코폴아민 및/또는 이것의 약제학적으로 허용될 수 있는 염이고, 부교감 신경 억제제가 피소스티그민 및/또는 이것의 약제학적으로 허용될 수 있는 염임을 특징으로 하는 약제 제형.
  10. 유기 인 콜린스테라아제 억제제에 의한 중독의 예방 및/또는 치료를 위한 약제의 제조를 위한 제1항 내지 제9항 중 어느 한 항에 따르는 제형의 사용 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960702987A 1993-12-10 1994-12-06 유기인콜린스테라아제억제제에의해야기되는중독의예방및예비치료를위한약제제형 KR100374086B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4342173.3 1993-12-10
DE4342173A DE4342173A1 (de) 1993-12-10 1993-12-10 Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer

Publications (2)

Publication Number Publication Date
KR960706341A true KR960706341A (ko) 1996-12-09
KR100374086B1 KR100374086B1 (ko) 2003-07-23

Family

ID=6504683

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702987A KR100374086B1 (ko) 1993-12-10 1994-12-06 유기인콜린스테라아제억제제에의해야기되는중독의예방및예비치료를위한약제제형

Country Status (22)

Country Link
US (1) US6114347A (ko)
EP (1) EP0732926B1 (ko)
JP (1) JP3709204B2 (ko)
KR (1) KR100374086B1 (ko)
AT (1) ATE232726T1 (ko)
AU (1) AU704020B2 (ko)
CA (1) CA2178605C (ko)
CZ (1) CZ291870B6 (ko)
DE (2) DE4342173A1 (ko)
DK (1) DK0732926T3 (ko)
ES (1) ES2193185T3 (ko)
FI (1) FI962369A (ko)
HU (1) HUT74427A (ko)
IL (1) IL111917A (ko)
MY (1) MY116828A (ko)
NO (1) NO962406D0 (ko)
NZ (1) NZ277258A (ko)
PL (1) PL314915A1 (ko)
PT (1) PT732926E (ko)
SK (1) SK282536B6 (ko)
WO (1) WO1995015756A1 (ko)
ZA (1) ZA949843B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100794891B1 (ko) * 2000-03-29 2008-01-14 페레르 인터내쇼날 에스.에이. 씨디피-콜린 또는 그의 약학적으로 수용 가능한 염을 포함하는 알코올 금단 증후군의 치료용 약제 및 치료 방법

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002316111A1 (en) * 2001-05-11 2002-11-25 Marvin B. Bacaner Novel therapeutical quaternary ammonium compositions
AU2003228796A1 (en) * 2002-05-01 2003-11-17 Eisai Co., Ltd. Cholinesterase inhibitors to prevent injuries caused by chemicals
DE10301851A1 (de) * 2003-01-17 2004-07-29 Lts Lohmann Therapie-Systeme Ag Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
US20050013869A1 (en) * 2003-07-18 2005-01-20 Chaw Cheng Shu Sustained release formulation for carbamates and a method therefor
WO2005027905A1 (en) * 2003-09-19 2005-03-31 The Secretary Of State For Defence Pharmaceutical compositions for the treatment of organophosphate poisoning
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
WO2006036686A2 (en) * 2004-09-24 2006-04-06 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
CN111773389A (zh) * 2020-06-02 2020-10-16 杨卫国 一种治疗牛中毒的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3760806A (en) * 1971-01-13 1973-09-25 Alza Corp Helical osmotic dispenser with non-planar membrane
US3760805A (en) * 1971-01-13 1973-09-25 Alza Corp Osmotic dispenser with collapsible supply container
US3764984A (en) * 1972-01-28 1973-10-09 Benz G Information coding system
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4137300A (en) * 1976-08-20 1979-01-30 Ciba-Geigy Corporation Sustained action dosage forms
JPS5935920B2 (ja) * 1978-12-01 1984-08-31 フアイザ−・インコ−ポレ−テツド ２−ケトグロネ−トの製造方法
JPS60189744A (ja) * 1984-03-09 1985-09-27 Tokyo Color:Kk カラ−写真現像液の再生方法
JPS62133457A (ja) * 1985-12-04 1987-06-16 Konishiroku Photo Ind Co Ltd ハロゲン化銀カラ−写真感光材料の処理方法及び現像液処理装置
JPH03194552A (ja) * 1989-12-22 1991-08-26 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料の処理方法
US5098819A (en) * 1990-01-31 1992-03-24 Knapp Audenried W Non-toxic photographic developer composition
US5278035A (en) * 1990-01-31 1994-01-11 Knapp Audenried W Non-toxic photographic developer composition for processing x-ray films in automatic film processors
DE4115558A1 (de) * 1991-05-13 1992-11-19 Dresden Arzneimittel Prophylaktisches antidot gegen phosphororganische gifte

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100794891B1 (ko) * 2000-03-29 2008-01-14 페레르 인터내쇼날 에스.에이. 씨디피-콜린 또는 그의 약학적으로 수용 가능한 염을 포함하는 알코올 금단 증후군의 치료용 약제 및 치료 방법

Also Published As

Publication number Publication date
HU9601599D0 (en) 1996-08-28
JP3709204B2 (ja) 2005-10-26
ES2193185T3 (es) 2003-11-01
CA2178605A1 (en) 1995-06-15
CA2178605C (en) 2006-02-14
US6114347A (en) 2000-09-05
JPH09506361A (ja) 1997-06-24
NZ277258A (en) 1999-09-29
AU704020B2 (en) 1999-04-15
CZ168396A3 (en) 1996-10-16
ATE232726T1 (de) 2003-03-15
ZA949843B (en) 1995-09-01
WO1995015756A1 (de) 1995-06-15
FI962369A (fi) 1996-08-02
DE59410246C5 (de) 2008-09-25
NO962406L (no) 1996-06-07
PT732926E (pt) 2003-06-30
IL111917A (en) 1998-08-16
DE4342173A1 (de) 1995-06-14
CZ291870B6 (cs) 2003-06-18
MY116828A (en) 2004-04-30
NO962406D0 (no) 1996-06-07
HUT74427A (en) 1996-12-30
AU1242495A (en) 1995-06-27
KR100374086B1 (ko) 2003-07-23
FI962369A0 (fi) 1996-06-07
SK282536B6 (sk) 2002-10-08
SK73896A3 (en) 1996-12-04
PL314915A1 (en) 1996-09-30
DK0732926T3 (da) 2003-06-10
EP0732926A1 (de) 1996-09-25
IL111917A0 (en) 1995-03-15
EP0732926B1 (de) 2003-02-19
DE59410246D1 (de) 2003-03-27

Similar Documents

Publication Publication Date Title
KR960706339A (ko) 고중독성 유기 인 신경독소, 특히 소만에 의해 야기되는 중독의 예방 및 예비 치료를 위한 피소스티그민 및 스코폴아민의 조합된 경피 투여를 위한 경피 치료 시스템 및 방법(transdermal therapeutical system for preventing poi-soning by organophosphoric nurotoxins that consists of a combination of active substances including a parasympat-homimetic and a parasympatholytic agent)
US6353004B1 (en) Peripherally acting anti-pruritic opiates
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
BR0213522A (pt) Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids
KR960706341A (ko) 유기 인 콜린스테라아제 억제제에 의해 야기되는 중독의 예방 및 예비 치료를 위한 약제 제형(pharmaceutical formulation for preventing or pre-treating poisoning by organophosphoric cholinesterase inhibitors)
DE69926750D1 (de) Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten
Horita et al. The interaction between reversible and irreversible monoamine oxidase inhibitors
US5849762A (en) Peripherally acting anti-pruritic opiates
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
RU94045866A (ru) Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, способ лечения
KR950016760A (ko) 치질 치료제
US4479956A (en) Analgesic compositions comprising propiram and methods of using same
KR920000326A (ko) 사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도
KR890009413A (ko) Ace억제제를 사용하는 불안 예방 또는 치료 방법
Witkin et al. Modulation of the lethal effects of cocaine by cholinomimetics
SK74399A3 (en) Novel therapeutic application of a thienycyclohexylamine derivative
Roath Management of Raynaud’s phenomenon: focus on newer treatments
CA1209047A (en) Therapeutic composition containing piracetam analog
US20010056091A1 (en) Therapeutic use of a thienylcyclohexylamine derivative
RU94046103A (ru) Содержащие четвертичный азот фосфонатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция, способ лечения
Booij et al. Antagonism of pancuronium and its metabolites by neostigmine in cats
Jović et al. Antidotal action of pyridinium oximes in poisoning by O, O-diethyl-s-[2-(N-methyl-N-phenylamino) ethyl] thiophosphonate methylsulfomethylate (GT-45) and its two new analogs
TH11815B (th) วิธียับยั้งการเกิดเนื้อเส้นใยผิดปกติที่มดลูก
MXPA99011155A (en) Peripherally acting anti-pruritic opiates
KR930700008A (ko) 상승작용 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100209

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee